Geoff G Z Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/252093/publications.pdf

Version: 2024-02-01

76 papers	5,199 citations	94433 37 h-index	82547 72 g-index
76 all docs	76 docs citations	76 times ranked	3415 citing authors

#	Article	IF	Citations
1	Impact of Surfactants on the Performance of Clopidogrel-Copovidone Amorphous Solid Dispersions: Increased Drug Loading and Stabilization of Nanodroplets. Pharmaceutical Research, 2022, 39, 167-188.	3.5	15
2	Role of Surfactants on Release Performance of Amorphous Solid Dispersions of Ritonavir and Copovidone. Pharmaceutical Research, 2022, 39, 381-397.	3.5	18
3	Phase separation in surfactant-containing amorphous solid dispersions: Orthogonal analytical methods to probe the effects of surfactants on morphology and phase composition. International Journal of Pharmaceutics, 2022, 619, 121708.	5.2	13
4	Polymorphic selectivity in crystal nucleation. Journal of Chemical Physics, 2022, 156, 144504.	3.0	17
5	Overcoming Bioavailability Challenges of Dasabuvir and Enabling a Triple-Combination Direct-Acting Antiviral HCV Regimen through a Salt of Very Weak Acid for Oral Delivery. Molecular Pharmaceutics, 2022, 19, 2367-2379.	4.6	3
6	Surfactants Accelerate Crystallization of Amorphous Nifedipine by Similar Enhancement of Nucleation and Growth Independent of Hydrophilicâ€“Lipophilic Balance. Molecular Pharmaceutics, 2022, 19, 2343-2350.	4.6	11
7	Anisotropic Molecular Organization at a Liquid/Vapor Interface Promotes Crystal Nucleation with Polymorph Selection. Journal of the American Chemical Society, 2022, 144, 11638-11645.	13.7	18
8	Expanding the Repertoire for â€œLarge Small Moleculesâ€• Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers. Molecular Cancer Therapeutics, 2021, 20, 999-1008.	4.1	12
9	Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Annals of Neurology, 2021, 90, 52-61.	5.3	33
10	Impact of Drugâ€“Polymer Intermolecular Interactions on Dissolution Performance of Copovidone-Based Amorphous Solid Dispersions. Molecular Pharmaceutics, 2021, 18, 3496-3508.	4.6	21
11	Effect of Polymers on Crystallization in Glass-Forming Molecular Liquids: Equal Suppression of Nucleation and Growth and Master Curve for Prediction. Crystal Growth and Design, 2020, 20, 237-244.	3.0	23
12	Impact of Monomeric versus Micellar Surfactant and Surfactantâ€“Polymer Interactions on Nucleationâ€“Induction Times of Atazanavir from Supersaturated Solutions. Crystal Growth and Design, 2020, 20, 62-72.	3.0	17
13	Evidence for Halogen Bonding in Amorphous Solid Dispersions. Crystal Growth and Design, 2020, 20, 3224-3235.	3.0	27
14	Assessing the Impact of Endogenously Derived Crystalline Drug on the in Vivo Performance of Amorphous Formulations. Molecular Pharmaceutics, 2019, 16, 3617-3625.	4.6	22
15	Insights into the Dissolution Behavior of Ledipasvirâ€“Copovidone Amorphous Solid Dispersions: Role of Drug Loading and Intermolecular Interactions. Molecular Pharmaceutics, 2019, 16, 5054-5067.	4.6	68
16	Phase Behavior of Amorphous Solid Dispersions of Felodipine: Homogeneity and Drugâ€“Polymer Interactions. Molecular Pharmaceutics, 2019, 16, 4836-4851.	4.6	28
17	Direct Visualization of Drugâ€“Polymer Phase Separation in Ritonavirâ€“Copovidone Amorphous Solid Dispersions Using in situ Synchrotron X-ray Fluorescence Imaging of Thin Films. Molecular Pharmaceutics, 2019, 16, 4751-4754.	4.6	9
18	Insights into the Dissolution Mechanism of Ritonavirâ€“Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance. Molecular Pharmaceutics, 2019, 16, 1327-1339.	4.6	106

#	Article	IF	Citations
19	Assessing Physical Stability Risk Using the Amorphous Classification System (ACS) Based on Simple Thermal Analysis. Molecular Pharmaceutics, 2019, 16, 2742-2754.	4.6	21
20	Assessing Physical Stability of Colloidal Dispersions Using a Turbiscan Optical Analyzer. Molecular Pharmaceutics, 2019, 16, 877-885.	4.6	47
21	Paclitaxel Crystal Seeds with Different Intrinsic Properties and Their Impact on Dissolution of Paclitaxel-HPMCAS Amorphous Solid Dispersions. Crystal Growth and Design, 2018, 18, 1548-1559.	3.0	37
22	Predictive Modeling of Micellar Solubilization by Single and Mixed Nonionic Surfactants. Journal of Pharmaceutical Sciences, 2018, 107, 2079-2090.	3.3	8
23	Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport. Journal of Controlled Release, 2018, 292, 172-182.	9.9	116
24	Crystal nucleation rates in glass-forming molecular liquids: D-sorbitol, D-arabitol, D-xylitol, and glycerol. Journal of Chemical Physics, 2018, 149, 054503.	3.0	43
25	An Intramolecular OHÂ·Â·Â·Ï€(arene) Interaction in a BINOLâ€“Phenazine Cocrystal with a â€œFreeâ€•N-Atom. Crystal Growth and Design, 2018, 18, 3890-3895.	3.0	3
26	Origin of Nanodroplet Formation Upon Dissolution of an Amorphous Solid Dispersion: A Mechanistic Isotope Scrambling Study. Journal of Pharmaceutical Sciences, 2017, 106, 1998-2008.	3.3	48
27	Reducing a cocrystal to nanoscale dimensions enables retention of physical crystal integrity upon dehydration. CrystEngComm, 2017, 19, 3723-3726.	2.6	2
28	Impact of Micellar Surfactant on Supersaturation and Insight into Solubilization Mechanisms in Supersaturated Solutions of Atazanavir. Pharmaceutical Research, 2017, 34, 1276-1295.	3.5	51
29	Influence of sample preparation on IGC measurements: the cases of silanised glass wool and packing structure. RSC Advances, 2017, 7, 12194-12200.	3.6	7
30	Pair distribution functions of amorphous organic thin films from synchrotron X-ray scattering in transmission mode. IUCrJ, 2017, 4, 555-559.	2.2	11
31	Exploiting the Phenomenon of Liquidâ€“Liquid Phase Separation for Enhanced and Sustained Membrane Transport of a Poorly Water-Soluble Drug. Molecular Pharmaceutics, 2016, 13, 2059-2069.	4.6	139
32	Modeling Physical Stability of Amorphous Solids Based onÂTemperature and Moisture Stresses. Journal of Pharmaceutical Sciences, 2016, 105, 2932-2939.	3.3	24
33	Physical chemistry of supersaturated solutions and implications for oral absorption. Advanced Drug Delivery Reviews, 2016, 101, 122-142.	13.7	286
34	Solvent compatible microfluidic platforms for pharmaceutical solid form screening. RSC Advances, 2016, 6, 13286-13296.	3.6	13
35	Impact of Solubilizing Additives on Supersaturation and Membrane Transport of Drugs. Pharmaceutical Research, 2015, 32, 3350-3364.	3.5	101
36	Crystallization Optimization of Pharmaceutical Solid Forms with X-ray Compatible Microfluidic Platforms. Crystal Growth and Design, 2015, 15, 1201-1209.	3.0	29

#	Article	IF	Citations
37	Using Environment-Sensitive Fluorescent Probes to Characterize Liquid-Liquid Phase Separation in Supersaturated Solutions of Poorly Water Soluble Compounds. Pharmaceutical Research, 2015, 32, 3660-3673.	3.5	40
38	Trends in the Precipitation and Crystallization Behavior of Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs Assessed Using Synchrotron Radiation. Journal of Pharmaceutical Sciences, 2015, 104, 1981-1992.	3.3	71
39	Enhancements and Limits in Drug Membrane Transport Using Supersaturated Solutions of Poorly Water Soluble Drugs. Journal of Pharmaceutical Sciences, 2014, 103, 2736-2748.	3.3	148
40	Synthon Hierarchies in Crystal Forms Composed of Theophylline and Hydroxybenzoic Acids: Cocrystal Screening via Solution-Mediated Phase Transformation. Crystal Growth and Design, 2014, 14, 5318-5328.	3.0	37
41	Impact of Polymers on the Crystallization and Phase Transition Kinetics of Amorphous Nifedipine during Dissolution in Aqueous Media. Molecular Pharmaceutics, 2014, 11, 3565-3576.	4.6	51
42	The curious case of (caffeine)Â·(benzoic acid): how heteronuclear seeding allowed the formation of an elusive cocrystal. Chemical Science, 2013, 4, 4417.	7.4	115
43	Supramolecular Complexes of Sulfadiazine and Pyridines: Reconfigurable Exteriors and Chameleon-like Behavior of Tautomers at the Co-Crystalâ€“Salt Boundary. Crystal Growth and Design, 2013, 13, 393-403.	3.0	41
44	Editorial. International Journal of Pharmaceutics, 2013, 442, 1-2.	5.2	0
45	â€˜Masked synthonsâ€™ in crystal engineering: insulated components in acetaminophen cocrystal hydrates. CrystEngComm, 2013, 15, 4816.	2.6	33
46	A Microfluidic Platform for Evaporation-based Salt Screening of Pharmaceutical Parent compounds. Lab on A Chip, 2013, 13, 1708.	6.0	20
47	Low-Concentration Polymers Inhibit and Accelerate Crystal Growth in Organic Glasses in Correlation with Segmental Mobility. Journal of Physical Chemistry B, 2013, 117, 10334-10341.	2.6	37
48	Microfluidic approach to polymorph screening through antisolvent crystallization. CrystEngComm, 2012, 14, 2404.	2.6	31
49	Characterizing the Impact of Hydroxypropylmethyl Cellulose on the Growth and Nucleation Kinetics of Felodipine from Supersaturated Solutions. Crystal Growth and Design, 2012, 12, 1538-1547.	3.0	120
50	Microfluidic Approach to Cocrystal Screening of Pharmaceutical Parent Compounds. Crystal Growth and Design, 2012, 12, 6023-6034.	3.0	36
51	A microfluidic platform for pharmaceutical salt screening. Lab on A Chip, 2011, 11, 3829.	6.0	38
52	Cocrystal Intrinsic Dissolution Behavior Using a Rotating Disk. Journal of Pharmaceutical Sciences, 2011, 100, 1736-1744.	3.3	46
53	Dissolution and Precipitation Behavior of Amorphous Solid Dispersions. Journal of Pharmaceutical Sciences, 2011, 100, 3316-3331.	3.3	231
54	A Novel Accelerated Oxidative Stability Screening Method for Pharmaceutical Solids. Journal of Pharmaceutical Sciences, 2011, 100, 3529-3538.	3.3	16

#	Article	IF	Citations
55	A 1:1 Cocrystal of Caffeine and 2-Hydroxy-1-Naphthoic Acid Obtained via a Slurry Screening Method. Journal of Chemical Crystallography, 2010, 40, 933-939.	1.1	31
56	Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution. Pharmaceutical Research, 2010, 27, 608-618.	3.5	395
57	Pharmaceutical Nanoâ€Cocrystals: Sonochemical Synthesis by Solvent Selection and Use of a Surfactant. Angewandte Chemie - International Edition, 2010, 49, 7284-7288.	13.8	78
58	A Red Zwitterionic Co-Crystal of Acetaminophen and 2,4-Pyridinedicarboxylic Acid. Journal of Pharmaceutical Sciences, 2010, 99, 3676-3683.	3.3	29
59	Solubilities of Crystalline Drugs in Polymers: An Improved Analytical Method and Comparison of Solubilities of Indomethacin and Nifedipine in PVP, PVP/VA, and PVAc. Journal of Pharmaceutical Sciences, 2010, 99, 4023-4031.	3.3	212
60	Chiral co-crystal solid solution: structures, melting point phase diagram, and chiral enrichment of (ibuprofen)2(4,4-dipyridyl). CrystEngComm, 2010, 12, 1485.	2.6	41
61	Solubility of Small-Molecule Crystals in Polymers: d-Mannitol in PVP, Indomethacin in PVP/VA, and Nifedipine in PVP/VA. Pharmaceutical Research, 2009, 26, 855-864.	3.5	183
62	Cocrystals of Caffeine and Hydroxybenzoic Acids Composed of Multiple Supramolecular Heterosynthons: Screening via Solution-Mediated Phase Transformation and Structural Characterization. Crystal Growth and Design, 2009, 9, 1932-1943.	3.0	111
63	Thermodynamics, Molecular Mobility and Crystallization Kinetics of Amorphous Griseofulvin. Molecular Pharmaceutics, 2008, 5, 927-936.	4.6	114
64	Co-Crystals of Caffeine and Hydroxy-2-naphthoic Acids:â€‰ Unusual Formation of the Carboxylic Acid Dimer in the Presence of a Heterosynthon. Molecular Pharmaceutics, 2007, 4, 339-346.	4.6	90
65	Determining the Growth Mechanism of Tolazamide by Induction Time Measurement. Crystal Growth and Design, 2007, 7, 234-242.	3.0	86
66	A Calorimetric Investigation of Thermodynamic andMolecular Mobility Contributions to the Physical Stability of Two Pharmaceutical Glasses. Journal of Pharmaceutical Sciences, 2007, 96, 71-83.	3.3	55
67	Crystallographic Characterization of Several Erythromycin A Solvates: The Environment of The Solvent Molecules in the Crystal Lattice. Journal of Pharmaceutical Sciences, 2007, 96, 1251-1257.	3.3	5
68	Efficient Co-crystal Screening Using Solution-Mediated Phase Transformation. Journal of Pharmaceutical Sciences, 2007, 96, 990-995.	3.3	185
69	Amphiphilic Block Copolymer as a Crystal Habit Modifier. Crystal Growth and Design, 2005, 5, 1781-1785.	3.0	22
70	Formation of Liquid Inclusions in Adipic Acid Crystals during Recrystallization from Aqueous Solutions. Crystal Growth and Design, 2005, 5, 319-324.	3.0	29
71	Phase transformation considerations during process development and manufacture of solid oral dosage forms. Advanced Drug Delivery Reviews, 2004, 56, 371-390.	13.7	376
72	Racemic species of sodium ibuprofen: Characterization and polymorphic relationships. Journal of Pharmaceutical Sciences, 2003, 92, 1356-1366.	3.3	51

#	ARTICLE	IF	CITATIONS
73	Model-free treatment of the dehydration kinetics of nedocromil sodium trihydrate. Journal of Pharmaceutical Sciences, 2003, 92, 1367-1376.	3.3	48
74	Crystallization and Transitions of Sulfamerazine Polymorphs. Journal of Pharmaceutical Sciences, 2002, 91, 1089-1100.	3.3	108
75	Physical Stability of Amorphous Pharmaceuticals: Importance of Configurational Thermodynamic Quantities and Molecular Mobility. Journal of Pharmaceutical Sciences, 2002, 91, 1863-1872.	3.3	292
76	In Situ Dehydration of Carbamazepine Dihydrate: A Novel Technique to Prepare Amorphous Anhydrous Carbamazepine. Pharmaceutical Development and Technology, 2000, 5, 257-266.	2.4	100